Table 1 Baseline subject characteristics, overall and by significant fibrosis as determined by AST-to-platelet ratio index (APRI) score (APRI >1.5).
From: Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients
Characteristic | All Subjects (n = 432) | APRI ≤ 1.5 (n = 396) | APRI >1.5 (n = 36) | P-Value |
|---|---|---|---|---|
Median age (yrs, IQR) | 38 (32-44) | 38 (31-44) | 39 (35-45) | 0.4 |
Male sex (no., %) | 254 (59%) | 228 (58%) | 26 (72%) | 0.09 |
Race (no., %) | Â | Â | Â | Â |
   African-American | 311 (72%) | 286 (72%) | 25 (69%) | 0.7 |
   Caucasian | 121 (28%) | 110 (28%) | 11 (31%) |  |
Hispanic (no., %) | 17 (4%) | 16 (4%) | 1 (3%) | 0.7* |
Alcohol use in last 30 days (no., %) | 185 (43%) | 167 (42%) | 18 (50%) | 0.4 |
Marijuana use in last 30 days (no., %) | 81 (19%) | 72 (18%) | 9 (25%) | 0.3 |
Diabetes mellitus (no., %) | 34 (8%) | 28 (7%) | 6 (17%) | 0.04 |
Body mass index (kg/m 2 , IQR) | Â | Â | Â | 0.1* |
   Underweight (≤ 18.4 kg/m2) | 15 (3%) | 14 (4%) | 1 (3%) |  |
   Ideal (18.5 kg/m2 - 24.9 kg/m2) | 202 (47%) | 179 (45%) | 23 (64%) |  |
   Overweight (25.0 kg/m2 - 29.9 kg/m2) | 135 (31%) | 128 (32%) | 7 (19%) |  |
   Obese (30 kg/m2 - 39.9 kg/m2) | 65 (15%) | 60 (15%) | 5 (14%) |  |
   Very Obese (≥ 40.0 kg/m2) | 15 (3%) | 15 (4%) | 0 |  |
Median duration of HIV (yrs, IQR) | 2 (1-7) | 2 (0-7) | 2 (0-9.5) | 0.8 |
On antiretroviral therapy (no., %) | 273 (63%) | 252 (63%) | 21 (58%) | 0.5 |
Lopinavir/ritonavir (no., %) | Â | Â | Â | Â |
   Prior | 175 (41%) | 159 (40%) | 16 (44%) | 0.6 |
   Current | 74 (17%) | 68 (17%) | 6 (17%) | 0.9 |
Nevirapine (no., %) | Â | Â | Â | Â |
   Prior | 67 (16%) | 61 (15%) | 6 (17%) | 0.8 |
   Current | 12 (3%) | 12 (3%) | 0 (0%) | 0.3* |
Didanosine (no., %) | Â | Â | Â | Â |
   Prior | 57 (13%) | 55 (14%) | 2 (6%) | 0.2* |
   Current | 11 (3%) | 11 (3%) | 0 (0%) | 0.3* |
Stavudine (no., %) | Â | Â | Â | Â |
   Prior | 84 (19%) | 78 (20%) | 6 (17%) | 0.7 |
   Current | 11 (3%) | 5 (2%) | 0 (0%) | 0.5* |
Zidovudine/lamivudine/abacavir (no., %) | Â | Â | Â | Â |
   Prior | 35 (8%) | 33 (8%) | 2 (6%) | 0.6 |
   Current | 8 (2%) | 8 (2%) | 0 (0%) | 0.4 |
Median CD4 count (cells/mm 3 , IQR) | 340 (177-516) | 342 (182-516) | 315 (58-534) | 0.3 |
CD4 count <200 cells/mm 3 (no., %) | 121 (28%) | 107 (27%) | 14 (39%) | 0.1 |
Median HIV viral load (copies/mL, IQR) | 4,950 (75-44,162) | 2,506 (75-33,228) | 38,517 (2,958-206,373) | 0.0004 |
HIV viral load category (no., %) | Â | Â | Â | Â |
   75-49,999 copies/mL | 331 (76%) | 311 (78%) | 20 (56%) | 0.003* |
   50,000-99,999 copies/mL | 33 (8%) | 30 (8%) | 3 (8%) |  |
   ≥ 100,000 copies/mL | 68 (16%) | 55 (14%) | 13 (36%) |  |
Detectable HIV viremia (>75 copies/mL) | 323 (75%) | 291 (73%) | 32 (89%) | 0.04 |
Median aspartate aminotransferase (U/L, IQR) | 39 (23-42) | 29 (23-37) | 84 (65-123) | <0.001 |
Median platelet count (×10 9 /L, IQR) | 232 (187-283) | 237 (197-287) | 130 (92-163) | <0.001 |
Median APRI | 0.42 (0.31-0.66) | 0.40 (0.30-0.59) | 2.1 (1.7-80-3.64) | <0.001 |